The 2018 annual cost burden for children under five years of age hospitalised with respiratory syncytial virus in Australia

Authors

  • Natasha K Brusco Alpha Crucis Group, Melbourne, Australia; Rehabilitation, Ageing and Independent Living (RAIL) Research Centre, School of Primary and Allied Health Care, Peninsula Campus, Monash University, Frankston, Australia
  • Annette Alafaci Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne Australia
  • Jane Tuckerman Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne Australia; Department of Paediatrics, University of Melbourne, Victoria. Australia
  • Helena Frawley School of Health Sciences, The University of Melbourne, Victoria, Australia
  • Jeremy Pratt Queensland Children’s Hospital, Brisbane, Victoria
  • Andrew J Daley Respiratory syncytial virus, respiratory infection, cost burden, economic evaluation, paediatrics; Department of Microbiology, Royal Children’s Hospital, Melbourne, Victoria, Australia
  • Angela K Todd WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Vic, Australia
  • Yi-Mo Deng WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Vic, Australia; Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia
  • Kanta Subbarao WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Vic, Australia; Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia
  • Ian Barr WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Vic, Australia; Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia
  • Nigel W Crawford Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne Australia; Department of Paediatrics, University of Melbourne, Victoria. Australia

DOI:

https://doi.org/10.33321/cdi.2022.46.5

Keywords:

Respiratory syncytial virus, respiratory infection, cost burden, economic evaluation, paediatrics

Abstract

Respiratory syncytial virus (RSV) is one of the principal causes of acute bronchiolitis and respiratory tract infections in young children. Routine RSV surveillance in Australian children is limited; vaccines are in late stage development; prophylactic monoclonal antibody (mAb) treatment is available but expensive; and there has been uncertainty around the cost burden. The objective of this study was to determine the annual cost burden for children under five years of age hospitalised with RSV in a single health service in 2018, with national extrapolation based on published Australian prevalence data. The methods utilised individual patient-level cost data prospectively collected for hospitalised children under five years of age in a tertiary Melbourne paediatric hospital. Results were extrapolated to all Australian children under five years of age to determine the national annual health cost burden, from a healthcare sector perspective over a 12 month time horizon. The results included 363 children with a mean age of 9.2 months (standard deviation, SD: 8.5 months). The mean cost per child was $17,120 (SD: $37,562), with a combined health service cost of $6,214,439. The reported Australian hospitalisation rate for RSV in the target age group ranged from 2.2 to 4.5 per 1,000 children under five years of age, resulting in a 2018 extrapolated cost range of $59,218,844–$121,129,453 for the estimated 3,459–7,075 children affected (combined index and all-cause six-month readmissions). This study concluded that RSV represents a significant cost burden to Australia’s health care system. These data are important for future health economic assessments of preventative therapies, such as new RSV mAb treatments and maternal/childhood RSV vaccines, and provides valuable insights to inform health care planning and health policy.

Downloads

Download data is not yet available.

References

Díez-Domingo J, Pérez-Yarza EG, Melero JA, Sánchez-Luna M, Aguilar MD, Blasco AJ et al. Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infect Dis. 2014;14:544. doi: https://doi.org/10.1186/s12879-014-0544-x.

Jepsen MT, Trebbien R, Emborg HD, Krause TG, Schønning K, Voldstedlund M et al. Incidence and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015. Euro Surveill. 2018;23(3). doi: https://doi.org/10.2807/1560-7917.ES.2018.23.3.17-00163.

Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics. 2004;22(5):275–84.

Shafique M, Zahoor MA, Arshad MI, Aslam B, Siddique AB, Rasool MH et al. Hurdles in vaccine development against respiratory syncytial virus. In Resch B, ed. The Burden of Respiratory Syncytial Virus Infection in the Young. London: IntechOpen; 2019.

Moore HC, Blyth CC. Assessing the burden of respiratory syncytial virus disease in Australia. Med J Aust. 2019;210(10):444–5.

Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child. 2003;88(12):1065–9.

Britton PN, Hu N, Saravanos G, Shrapnel J, Davis J, Snelling T et al. COVID-19 public health measures and respiratory syncytial virus. Lancet Child Adolesc Health. 2020;4(11):e42–3.

Yeoh DK, Foley DA, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT et al. The impact of COVID-19 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter. Clin Infect Dis. 2020. doi: https://doi.org/10.1093/cid/ciaa1475.

McNab S, Do LAH, Clifford V, Crawford NW, Daley A, Mulholland K et al. Changing epidemiology of pespiratory syncytial virus in Australia—delayed re-emergence in Victoria compared to WA/NSW after prolonged lock-down for COVID-19. Clin Infect Dis. 2021. doi: https://doi.org/10.1093/cid/ciab240.

Foley DA, Yeoh DK, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT et al. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. Clin Infect Dis. 2021. doi: https://doi.org/10.1093/cid/ciaa1906.

McNamara PS, Smyth RL. The pathogenesis of respiratory syncytial virus disease in childhood. Br Med Bull. 2002;61:13–28.

Shefali-Patel D, Paris MA, Watson F, Peacock JL, Campbell M, Greenough A. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr. 2012;171(7):1055–61.

Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58.

Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–55.

Downloads

Published

16/02/22

How to Cite

Brusco, Natasha K, Annette Alafaci, Jane Tuckerman, Helena Frawley, Jeremy Pratt, Andrew J Daley, Angela K Todd, et al. 2022. “The 2018 Annual Cost Burden for Children under Five Years of Age Hospitalised With Respiratory Syncytial Virus in Australia ”. Communicable Diseases Intelligence 46 (February). https://doi.org/10.33321/cdi.2022.46.5.

Issue

Vol. 46 (2022)

Section

Original article

Categories

License

Copyright (c) 2022 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 > >>